| scholarly article | Q13442814 |
| P2093 | author name string | Kazuki Nabeshima | |
| Satoshi Nimura | |||
| Manabu Nakashima | |||
| Kazuhiko Ono | |||
| Yuko Hideshima | |||
| P2860 | cites work | Inflammatory Bowel Disease | Q22248115 |
| Clinical and experimental applications of sodium phenylbutyrate | Q24613511 | ||
| Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults | Q26768280 | ||
| Environmental risk factors for inflammatory bowel diseases: a review | Q26864725 | ||
| Inflammatory pathways of importance for management of inflammatory bowel disease | Q27005445 | ||
| Sodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson's disease | Q27301885 | ||
| Intestinal homeostasis and its breakdown in inflammatory bowel disease | Q29620336 | ||
| Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis | Q30304298 | ||
| Therapy of inflammatory bowel disease. | Q33951455 | ||
| Optimizing anti-TNF treatment in inflammatory bowel disease | Q35787448 | ||
| Immunopathogenesis of IBD: current state of the art. | Q35857951 | ||
| Sodium 4-phenylbutyrate prevents murine dietary steatohepatitis caused by trans-fatty acid plus fructose. | Q36265379 | ||
| Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate. | Q36569505 | ||
| Management of inflammatory bowel disease in adults | Q36833342 | ||
| Biologic targeting in the treatment of inflammatory bowel diseases. | Q37303206 | ||
| Inflammatory bowel disease: pathogenesis | Q37454586 | ||
| Selecting appropriate anti-TNF agents in inflammatory bowel disease | Q37503367 | ||
| Inflammatory bowel disease pathogenesis: what is new? | Q38008941 | ||
| Crosstalk between the intestinal microbiota and the innate immune system in intestinal homeostasis and inflammatory bowel disease | Q38106562 | ||
| Inflammatory bowel disease: etiology, pathogenesis and current therapy. | Q38115602 | ||
| Immuno-genomic profiling of patients with inflammatory bowel disease: a systematic review of genetic and functional in vivo studies of implicated genes | Q38244620 | ||
| Phenylbutyric Acid: simple structure - multiple effects. | Q38306960 | ||
| Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: a prospective cohort study. | Q39889565 | ||
| Anti-inflammatory effects of short chain fatty acids in IFN-gamma-stimulated RAW 264.7 murine macrophage cells: involvement of NF-kappaB and ERK signaling pathways | Q40197858 | ||
| Sodium 4-phenylbutyrate suppresses the development of dextran sulfate sodium-induced colitis in mice | Q41942519 | ||
| Clinicopathologic study of dextran sulfate sodium experimental murine colitis. | Q42506472 | ||
| Chemically induced mouse models of intestinal inflammation | Q42510602 | ||
| Effects of 4-phenylbutyric acid on the process and development of diabetic nephropathy induced in rats by streptozotocin: regulation of endoplasmic reticulum stress-oxidative activation | Q43095387 | ||
| Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial | Q44387824 | ||
| A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human alpha-synuclein A30P + A53T transgenic mice. | Q46061994 | ||
| Colonic explant production of IL-1and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD). | Q47901523 | ||
| Interleukin-1beta targets interleukin-6 in progressing dextran sulfate sodium-induced experimental colitis. | Q53655073 | ||
| Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease | Q57265459 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 5485-5490 | |
| P577 | publication date | 2017-10-03 | |
| P1433 | published in | Experimental and Therapeutic Medicine | Q23979083 |
| P1476 | title | Orally administered sodium 4-phenylbutyrate suppresses the development of dextran sulfate sodium-induced colitis in mice | |
| P478 | volume | 14 |
| Q91671623 | Intrarectally administered polaprezinc attenuates the development of dextran sodium sulfate-induced ulcerative colitis in mice | cites work | P2860 |
Search more.